Rostami A M, Burns J B, Eccleston P A, Manning M C, Lisak R P, Silberberg D H
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia.
Ann Neurol. 1987 Sep;22(3):381-3. doi: 10.1002/ana.410220316.
To determine if galactocerebroside (GalC) is a target antigen in the human demyelinating disorders multiple sclerosis, Guillain-Barré syndrome, and chronic demyelinating inflammatory polyneuropathy, we examined the serum and cerebrospinal fluid from patients with these disorders and from control subjects using four assay systems. In none of these assays could we detect significant differences in anti-GalC antibody titer between patients with demyelinating diseases and normal subjects or patients with other neurological disorders. Our data suggest that there is no humoral immune response to GalC in human demyelinating disorders.
为了确定半乳糖脑苷脂(GalC)是否为人类脱髓鞘疾病(多发性硬化症、吉兰-巴雷综合征和慢性脱髓鞘性炎性多神经病)中的靶抗原,我们使用四种检测系统检测了这些疾病患者以及对照受试者的血清和脑脊液。在这些检测中,我们均未发现脱髓鞘疾病患者与正常受试者或其他神经系统疾病患者之间抗GalC抗体滴度存在显著差异。我们的数据表明,在人类脱髓鞘疾病中不存在针对GalC的体液免疫反应。